Literature DB >> 27688181

Synthesis and evaluation of C9 alkoxy analogues of (-)-stepholidine as dopamine receptor ligands.

Sudharshan Madapa1, Satishkumar Gadhiya2, Thomas Kurtzman3, Ian L Alberts4, Steven Ramsey5, Maarten Reith6, Wayne W Harding7.   

Abstract

Tetrahydroprotoberberine alkaloids have shown interesting polypharmacological actions at dopamine receptors and are a unique template from which to mine novel molecules with dual selective actions at D1 and D3 receptors. Such compounds will be valuable to evaluate as anti-cocaine therapeutics. Towards that eventual goal, we engaged an SAR study in which a series of C9 alkoxy analogues of the D1/D2/D3 ligand (-)-stepholidine that possessed or lacked a C12 bromo functionality, were synthesized and evaluated for affinity at dopamine D1, D2 and D3 receptors. We found that the analogues are generally selective for the D1 receptor. Small n-alkoxy substituents (up to 4 carbons in length) were generally well tolerated for high D1 affinity but such groups reduced D3 affinity. In the case of C12 brominated analogues, C9 alkoxylation also had little effect on D1 affinity for the smaller alkoxy groups, but reduced D2 and D3 affinities significantly. C12 bromination tends to increase D1 receptor selectivity. A number of compounds were identified that retain affinity for D1 and D3 receptors but lack D2 receptor affinity. Among them, compound 22a was found to be a selective D1/D3 dual antagonist (Ki = 5.3 and 106 nM at D1 and D3 receptors). Docking studies performed on the analogues at the D3 receptor revealed a number of interactions that are important for affinity including a critical N - Asp110 salt bridge motif, H-bonds to Ser192 and Cys181 and hydrophobic interactions between the aryl rings and Phe106 and Phe345. The analogues adopt an orientation in which ring A is located in the orthosteric binding site while the C9 alkoxy substituents attached to ring D project into the secondary binding pocket of the D3 receptor. Copyright Â
© 2016 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  D1; D3; Dopamine; Stepholidine; THPB; Tetrahydroprotoberberine

Mesh:

Substances:

Year:  2016        PMID: 27688181      PMCID: PMC5148686          DOI: 10.1016/j.ejmech.2016.09.036

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  45 in total

1.  The Protein Data Bank.

Authors:  H M Berman; J Westbrook; Z Feng; G Gilliland; T N Bhat; H Weissig; I N Shindyalov; P E Bourne
Journal:  Nucleic Acids Res       Date:  2000-01-01       Impact factor: 16.971

2.  Development and testing of a general amber force field.

Authors:  Junmei Wang; Romain M Wolf; James W Caldwell; Peter A Kollman; David A Case
Journal:  J Comput Chem       Date:  2004-07-15       Impact factor: 3.376

3.  Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy.

Authors:  Richard A Friesner; Jay L Banks; Robert B Murphy; Thomas A Halgren; Jasna J Klicic; Daniel T Mainz; Matthew P Repasky; Eric H Knoll; Mee Shelley; Jason K Perry; David E Shaw; Perry Francis; Peter S Shenkin
Journal:  J Med Chem       Date:  2004-03-25       Impact factor: 7.446

4.  Further delineation of hydrophobic binding sites in dopamine D(2)/D(3) receptors for N-4 substituents on the piperazine ring of the hybrid template 5/7-{[2-(4-aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro-naphthalen-2-ol.

Authors:  Balaram Ghosh; Tamara Antonio; Bhaskar Gopishetty; Maarten Reith; Aloke Dutta
Journal:  Bioorg Med Chem       Date:  2010-06-12       Impact factor: 3.641

5.  Stability of avoidance behaviour following repeated intermittent treatment with clozapine, olanzapine or D,L-govadine.

Authors:  Donovan M Ashby; Christopher C Lapish; Anthony G Phillips
Journal:  Behav Pharmacol       Date:  2015-02       Impact factor: 2.293

Review 6.  Halogen bonding (X-bonding): a biological perspective.

Authors:  Matthew R Scholfield; Crystal M Vander Zanden; Megan Carter; P Shing Ho
Journal:  Protein Sci       Date:  2012-12-29       Impact factor: 6.725

7.  Asymmetric total synthesis and identification of tetrahydroprotoberberine derivatives as new antipsychotic agents possessing a dopamine D(1), D(2) and serotonin 5-HT(1A) multi-action profile.

Authors:  Haifeng Sun; Liyuan Zhu; Huicui Yang; Wangke Qian; Lin Guo; Shengbin Zhou; Bo Gao; Zeng Li; Yu Zhou; Hualiang Jiang; Kaixian Chen; Xuechu Zhen; Hong Liu
Journal:  Bioorg Med Chem       Date:  2012-12-21       Impact factor: 3.641

8.  Tetrahydroprotoberberine--a new chemical type of antagonist of dopamine receptors.

Authors:  G Z Jin; X L Wang; W X Shi
Journal:  Sci Sin B       Date:  1986-05

9.  2,3,9- and 2,3,11-trisubstituted tetrahydroprotoberberines as D2 dopaminergic ligands.

Authors:  Javier Párraga; Nuria Cabedo; Sebastián Andujar; Laura Piqueras; Laura Moreno; Abraham Galán; Emilio Angelina; Ricardo D Enriz; María Dolores Ivorra; María Jesús Sanz; Diego Cortes
Journal:  Eur J Med Chem       Date:  2013-08-11       Impact factor: 6.514

10.  Levo-tetrahydropalmatine attenuates cocaine self-administration and cocaine-induced reinstatement in rats.

Authors:  John R Mantsch; Shi-Jiang Li; Robert Risinger; Sarah Awad; Eric Katz; David A Baker; Zheng Yang
Journal:  Psychopharmacology (Berl)       Date:  2007-03-15       Impact factor: 4.415

View more
  2 in total

Review 1.  Deep Learning in Drug Discovery and Medicine; Scratching the Surface.

Authors:  Dibyendu Dana; Satishkumar V Gadhiya; Luce G St Surin; David Li; Farha Naaz; Quaisar Ali; Latha Paka; Michael A Yamin; Mahesh Narayan; Itzhak D Goldberg; Prakash Narayan
Journal:  Molecules       Date:  2018-09-18       Impact factor: 4.411

2.  Inclusion of enclosed hydration effects in the binding free energy estimation of dopamine D3 receptor complexes.

Authors:  Rajat Kumar Pal; Satishkumar Gadhiya; Steven Ramsey; Pierpaolo Cordone; Lauren Wickstrom; Wayne W Harding; Tom Kurtzman; Emilio Gallicchio
Journal:  PLoS One       Date:  2019-09-30       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.